CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
House Dust Mite Allergen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05019209
NCT05019209N/ACompleted

Chamber Exposure with House Dust Mite (HDM) or Allergen-free Air in Atopic Drmatitis Patients with HDM Sensitization to Investigate the Role of Aeroallergen Exposure on Skin Responses and T Cell Immunology

Fraunhofer-Institute of Toxicology and Experimental Medicine·interventional·Posted Aug 24, 2021·Updated Oct 15, 2024

In Brief

A clinical study evaluating House Dust Mite Allergen and Allergen-free air for Atopic Dermatitis and House Dust Mite Allergy. Completed, enrolled 23 participants across 2 sites.

Detailed Summary

The present study investigates the reaction of the skin upon exposure to house dust mite (HDM) in patients with atopic dermatitis who have antibodies against HDM in the blood. A further aim is to assess nasal symptoms after exposure to HDM in an allergen challenge chamber and compare the results with data from previous studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 24, 2021
Enrollment StartSep 10, 2021
Primary CompletionFeb 14, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.9 years ago

Interventions

House Dust Mite Allergendrug

D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried

Allergen-free airother

No allergen added to room ventilation of allergen challenge chamber